stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) Operating cash flow
Palvella Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$25.0M, compared with −$10.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$36.5M. Over the past ten years it has ranged from −$59.9M (fiscal 2022) to $49.8M (fiscal 2017); the current reading is higher than 36% of that period. Palvella Therapeutics, Inc. ranks 306th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$25.0M | — |
| FY2024 | −$10.8M | — |
| FY2023 | −$13.7M | — |
| FY2022 | −$59.9M | — |
| FY2021 | −$7.7M | — |
| FY2020 | −$45.9M | — |
| FY2019 | −$52.5M | — |
| FY2018 | −$1.1M | — |
| FY2017 | $49.8M | — |
| FY2016 | −$14.4M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$12.8M | — |
| Mar 2026 | −$10.9M | — |
| Dec 2025 | −$4.9M | — |
| Sep 2025 | −$7.9M | — |
| 41 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.2M |
| ADMA ADMA Biologics Inc compare | $140.8M |
| VCEL Vericel Corporation compare | $65.3M |
| PVLA Palvella Therapeutics, Inc. | −$36.5M |
| PHVS Pharvaris N.V. compare | −$178.0M |
| IMNM Immunome, Inc. compare | −$208.8M |
| CLDX Celldex Therapeutics, Inc. compare | −$235.6M |
| VERA Vera Therapeutics, Inc. compare | −$338.7M |
| BHVN Biohaven Ltd. compare | −$472.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement